Advertisement

Evaluation of Disease Lesions in the Developing Canine MPS IIIA Brain

  • Leanne K. Winner
  • Neil R. Marshall
  • Robert D. Jolly
  • Paul J. Trim
  • Stephen K. Duplock
  • Marten F. Snel
  • Kim M. HemsleyEmail author
Research Report
Part of the JIMD Reports book series (JIMD, volume 43)

Abstract

Mucopolysaccharidosis IIIA (MPS IIIA) is an inherited neurodegenerative disease of childhood that results in early death. Post-mortem studies have been carried out on human MPS IIIA brain, but little is known about early disease development. Here, we utilised the Huntaway dog model of MPS IIIA to evaluate disease lesion development from 2 to 24 weeks of age. A significant elevation in primarily stored heparan sulphate was observed in all brain regions assessed in MPS IIIA pups ≤9.5 weeks of age. There was a significant elevation in secondarily stored ganglioside (GM3 36:1) in ≤9.5-week-old MPS IIIA pup cerebellum, and other brain regions also exhibited accumulation of this lipid with time. The number of neural stem cells and neuronal precursor cells was essentially unchanged in MPS IIIA dog brain (c.f. unaffected) over the time course assessed, a finding corroborated by neuron cell counts. We observed early neuroinflammatory changes in young MPS IIIA pup brain, with significantly increased numbers of activated microglia recorded in all but one brain region in MPS IIIA pups ≤9.5 weeks of age (c.f. age-matched unaffected pups). In conclusion, infant-paediatric-stage MPS IIIA canine brain exhibits substantial and progressive primary and secondary substrate accumulation, coupled with early and robust microgliosis. Whilst early initiation of treatment is likely to be required to maintain optimal neurological function, the brain’s neurodevelopmental potential appears largely unaffected by the disease process; further investigations confirming this are warranted.

Keywords

Brain development Dog Ganglioside Heparan sulphate Lysosome Microglia Mucopolysaccharidosis Neuroinflammation 

Abbreviations

CA3

Cornus ammonis region 3

CV

Coefficient of variation

FGF-2

Fibroblast growth factor 2

Ganglioside species

GD1, GM1, GM2, GM3, GT1

GC

Glucosylceramide

GlcSph

Glucosylsphingosine

LC

Lactosylceramide

LIMP-2

Lysosomal integral membrane protein-2

MPS-IIIA

Mucopolysaccharidosis type IIIA

NeuN

Neuronal nuclear antigen

PC

Phosphatidylcholine

PE

Phosphatidylethanolamine

PG

Phosphatidylglycerol

PI

Phosphatidylinositol

PS

Phosphatidylserine

SGSH

Sulphamidase

SM

Sphingomyelin

Supplementary material

477606_1_En_110_MOESM1_ESM.docx (493 kb)
Supplementary Fig. 1 Quantification of GM2 38:1 and GM3 38:1 in 2–24-week-old unaffected and MPS IIIA dog brain (af) and spinal cord (g, h). Each data point reflects a single dog. Six-week-old unaffected dog hippocampus was unavailable for study. The spinal cord was prepared in a separate batch from the brain (hippocampus, cortex and cerebellum). Two QC samples (MPS IIIA dog hippocampus) were run with each batch; both batches were analysed on the same day (DOCX 492 kb)
477606_1_En_110_MOESM2_ESM.docx (84 kb)
Supplementary Fig. 2 Quantification of the ganglioside GM3 precursors: (a) glucosylceramide (GC), and (b) lactosylceramide (LC); in addition to the most abundant species of phospholipids, (c) phosphatidylethanolamine (PE), and (d) phosphatidylinositol (PI), in the 2–24-week-old MPS IIIA and unaffected dog cerebellum. Each data point reflects a single dog (DOCX 83 kb)
477606_1_En_110_MOESM3_ESM.docx (559 kb)
Supplementary Fig. 3 Quantification of lipids in cerebellar samples taken from 2- to 24-week-old unaffected and MPS IIIA dogs. Each data point reflects a single dog. (ad) Glucosylceramide (GC), (eg) lactosylceramide (LC), (h) glucosylsphingosine (GlcSph) and (ij) sphingomyelin (SM) (DOCX 559 kb)
477606_1_En_110_MOESM4_ESM.docx (619 kb)
Supplementary Fig. 4 Quantification of phospholipids in cerebellar homogenates taken from unaffected and MPS IIIA dogs aged 2–24 weeks. Each data point reflects a single dog. (ac) Phosphatidylethanolamine (PE), (dg) phosphatidylinositol (PI) and (hk) phosphatidylserine (PS). The inter-assay CV for PE species was <14.1%, for PI species <12.1% and for PS species <13% (DOCX 618 kb)
477606_1_En_110_MOESM5_ESM.docx (316 kb)
Supplementary Fig. 5 Quantification of phospholipids in 2–24-week-old unaffected and MPS IIIA dog cerebellum. Each data point reflects a single dog. (ad) Phosphatidylcholine (PC) and (ei) phosphatidylglycerol (PG) (DOCX 316 kb)
477606_1_En_110_MOESM6_ESM.docx (4.5 mb)
Supplementary Fig. 6 Quantification of LIMP-2 immunoreactivity in various brain regions with time (ae). Each data point reflects a single dog. Filled square 2-week-old pups, filled circle 4-week-old pups, filled triangle 6-week-old pups, filled diamond 9.5-week-old pups, filled inverted triangle 24-week-old pups. The photos in (f) show the location of the brain regions assessed: (a) gyrus suprasylvius anterior, (b) gyrus suprasylvius medialis, (c) polymorphic cell layer (hilus), (d) lobe 6 of the cerebellum and (e) caudate nucleus head. Photos in (g) and (h) show LIMP-2 staining in the gyrus suprasylvius anterior of 24-week-old unaffected and MPS IIIA dog brain (respectively). *p < 0.05, **p < 0.01 (DOCX 4573 kb)
477606_1_En_110_MOESM7_ESM.docx (1.5 mb)
Supplementary Fig. 7 Quantification of doublecortin immunoreactivity in various brain regions (a, b, d, e, g, h and jl). Each data point reflects a single dog. The photos show doublecortin staining in the unaffected (c) and MPS IIIA (f) gyrus suprasylvius anterior at 2 weeks of age. The photos in (i) show the location of the brain regions assessed: (a) gyrus suprasylvius anterior, (b) gyrus suprasylvius medialis, (d) CA3, (e) dentate gyrus, (g) subventricular zone, (h) fasciculus subcallosus, (jk) lobe 6 of the cerebellum and (l) caudate nucleus head (DOCX 1516 kb)
477606_1_En_110_MOESM8_ESM.docx (14 kb)
Supplementary Table 1 Ganglioside species assessed are listed in order of abundance, together with the inter-assay coefficient of variation for that species (DOCX 14 kb)
477606_1_En_110_MOESM9_ESM.docx (23 kb)
Supplementary Methods (DOCX 22 kb)

References

  1. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917CrossRefGoogle Scholar
  2. Ceuterick C, Martin JJ, Libert J, Farriaux JP (1980) Sanfilippo A disease in the fetus – comparison with pre- and postnatal cases. Neuropadiatrie 11:176–185CrossRefGoogle Scholar
  3. Clancy B, Finlay BL, Darlington RB, Anand KJ (2007) Extrapolating brain development from experimental species to humans. Neurotoxicology 28:931–937CrossRefGoogle Scholar
  4. Crawley AC, Gliddon BL, Auclair D et al (2006) Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104:1–17CrossRefGoogle Scholar
  5. Crawley AC, Marshall N, Beard H et al (2011) Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol Dis 43:422–434CrossRefGoogle Scholar
  6. Dale GL, Villacorte DG, Beutler E (1976) Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity. Biochem Biophys Res Commun 71:1048–1053CrossRefGoogle Scholar
  7. Dawson G, Fuller M, Helmsley KM, Hopwood JJ (2012) Abnormal gangliosides are localized in lipid rafts in Sanfilippo (MPS3a) mouse brain. Neurochem Res 37:1372–1380CrossRefGoogle Scholar
  8. De Nevi E, Marco-Salazar P, Fondevila D, Blasco E, Perez L, Pumarola M (2013) Immunohistochemical study of doublecortin and nucleostemin in canine brain. Eur J Histochem 57:e9CrossRefGoogle Scholar
  9. Duffy TE, Cavazzuti M, Cruz NF, Sokoloff L (1982) Local cerebral glucose metabolism in newborn dogs: effects of hypoxia and halothane anesthesia. Ann Neurol 11:233–246CrossRefGoogle Scholar
  10. Greenwood RS, Hillman RE, Alcala H, Sly WS (1978) Sanfilippo A syndrome in the fetus. Clin Genet 13:241–250CrossRefGoogle Scholar
  11. Hassiotis S, Jolly RD, Hemsley KM (2014) Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA). Mol Genet Metab 113:283–293CrossRefGoogle Scholar
  12. Horesh D, Sapir T, Francis F et al (1999) Doublecortin, a stabilizer of microtubules. Hum Mol Genet 8:1599–1610CrossRefGoogle Scholar
  13. Jean DC, Baas PW, Black MM (2012) A novel role for doublecortin and doublecortin-like kinase in regulating growth cone microtubules. Hum Mol Genet 21:5511–5527CrossRefGoogle Scholar
  14. Jin K, Sun Y, Xie L et al (2003) Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2:175–183CrossRefGoogle Scholar
  15. Jolly RD, Shimada A, Dopfmer I, Slack PM, Birtles MJ, Palmer DN (1989) Ceroid-lipofuscinosis (Batten’s disease): pathogenesis and sequential neuropathological changes in the ovine model. Neuropathol Appl Neurobiol 15:371–383CrossRefGoogle Scholar
  16. Jolly RD, Allan FJ, Collett MG, Rozaklis T, Muller VJ, Hopwood JJ (2000) Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia. N Z Vet J 48:144–148CrossRefGoogle Scholar
  17. Kay GW, Palmer DN, Rezaie P, Cooper JD (2006) Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis. Brain Pathol 16:110–116CrossRefGoogle Scholar
  18. Kennedy C, Sakurada O, Shinohara M, Jehle J, Sokoloff L (1978) Local cerebral glucose utilization in the normal conscious macaque monkey. Ann Neurol 4:293–301CrossRefGoogle Scholar
  19. Kondagari GS, Yang J, Taylor RM (2011) Investigation of cerebrocortical and cerebellar pathology in canine fucosidosis and comparison to aged brain. Neurobiol Dis 41:605–613CrossRefGoogle Scholar
  20. Li HH, Zhao HZ, Neufeld EF, Cai Y, Gomez-Pinilla F (2002) Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. J Neurosci Res 69:30–38CrossRefGoogle Scholar
  21. Lockard I (1977) Desk reference for neuroanatomy: a guide to essential terms. Springer, New YorkCrossRefGoogle Scholar
  22. McCarty DM, DiRosario J, Gulaid K et al (2011) Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. Metab Brain Dis 26:9–19CrossRefGoogle Scholar
  23. McGlynn R, Dobrenis K, Walkley SU (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480:415–426CrossRefGoogle Scholar
  24. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254CrossRefGoogle Scholar
  25. Mercier F, Arikawa-Hirasawa E (2012) Heparan sulfate niche for cell proliferation in the adult brain. Neurosci Lett 510:67–72CrossRefGoogle Scholar
  26. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR (ed) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York, pp 3421–3452Google Scholar
  27. Schneider-Jakob HR, Cantz M (1991) Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors. Biol Chem Hoppe Seyler 372:443–450CrossRefGoogle Scholar
  28. Singer M (1962) The brain of the dog in section. W.B. Saunders, Philadelphia and LondonGoogle Scholar
  29. Sokoloff L, Reivich M, Kennedy C et al (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916CrossRefGoogle Scholar
  30. Toriyama M, Mizuno N, Fukami T et al (2012) Phosphorylation of doublecortin by protein kinase A orchestrates microtubule and actin dynamics to promote neuronal progenitor cell migration. J Biol Chem 287:12691–12702CrossRefGoogle Scholar
  31. Trim PJ, Lau AA, Hopwood JJ, Snel MF (2014) A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA. Rapid Commun Mass Spectrom 28:933–938CrossRefGoogle Scholar
  32. Wood SL, Beyer BK, Cappon GD (2003) Species comparison of postnatal CNS development: functional measures. Birth Defects Res B Dev Reprod Toxicol 68:391–407CrossRefGoogle Scholar
  33. Yogalingam G, Pollard T, Gliddon B, Jolly RD, Hopwood JJ (2002) Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs. Genomics 79:150–153CrossRefGoogle Scholar

Copyright information

© Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018

Authors and Affiliations

  • Leanne K. Winner
    • 1
  • Neil R. Marshall
    • 2
  • Robert D. Jolly
    • 2
  • Paul J. Trim
    • 1
  • Stephen K. Duplock
    • 1
  • Marten F. Snel
    • 1
  • Kim M. Hemsley
    • 1
    Email author
  1. 1.Lysosomal Diseases Research UnitSouth Australian Health and Medical Research InstituteAdelaideAustralia
  2. 2.Institute of Veterinary, Animal and Biomedical Science, Massey UniversityPalmerston NorthNew Zealand

Personalised recommendations